

# Ethanol metabolism and its effects on the intestinal epithelial barrier

Elhaseen E Elamin, Ad A Masclee, Jan Dekker, and Daisy M Jonkers

*Ethanol is widely consumed and is associated with an increasing global health burden. Several reviews have addressed the effects of ethanol and its oxidative metabolite, acetaldehyde, on the gastrointestinal (GI) tract, focusing on carcinogenic effects or alcoholic liver disease. However, both the oxidative and the non-oxidative metabolites of ethanol can affect the epithelial barrier of the small and large intestines, thereby contributing to GI and liver diseases. This review outlines the possible mechanisms of ethanol metabolism as well as the effects of ethanol and its metabolites on the intestinal barrier. Limited studies in humans and supporting in vitro data have indicated that ethanol as well as mainly acetaldehyde can increase small intestinal permeability. Limited evidence also points to increased colon permeability following exposure to ethanol or acetaldehyde. In vitro studies have provided several mechanisms for disruption of the epithelial barrier, including activation of different cell-signaling pathways, oxidative stress, and remodeling of the cytoskeleton. Modulation via intestinal microbiota, however, should also be considered. In conclusion, ethanol and its metabolites may act additively or even synergistically in vivo. Therefore, in vivo studies investigating the effects of ethanol and its byproducts on permeability of the small and large intestines are warranted.*

© 2013 International Life Sciences Institute

## INTRODUCTION

Beverages containing ethanol (i.e., ethyl alcohol) are widely consumed in many parts of the world, creating an increasing global health burden. It has been estimated that around two billion people drink ethanol on a regular basis.<sup>1</sup> Ethanol consumption has long been recognized as a major cause of liver disease,<sup>2–4</sup> but it can also affect the gastrointestinal (GI) tract and is associated with the development of oral, esophageal, and colorectal cancers.<sup>5</sup> Ethanol as well as its metabolites can cause damage that includes decreased intestinal motility and cytotoxic and mutagenic effects.<sup>5–7</sup> Another important effect is the

ethanol-induced disruption of the epithelial barrier of the GI tract.<sup>8</sup> Studies performed in humans,<sup>9,10</sup> but mostly in animals,<sup>11–13</sup> have shown that both short- and long-term ethanol administration can result in increased intestinal permeability, which will ultimately enhance the translocation of luminal antigens (e.g., bacteria and endotoxins) into the portal circulation.<sup>14,15</sup> This can activate Kupffer's cells, subsequently leading to cytokine release, which results in hepatocellular injury and, consequently, alcoholic liver disease (ALD).<sup>16,17</sup> Data from human and animal studies indicate that increased intestinal permeability is also involved in inflammatory intestinal disorders such as inflammatory bowel disease<sup>18</sup> and irritable

Affiliations: *EE Elamin*, *AA Masclee*, and *DM Jonkers* are with the Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands, and the Division of Gastroenterology-Hepatology, School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands. *J Dekker* is with the Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands, and Host-Microbe Interactomics, Department of Animal Sciences, Wageningen University, Wageningen, The Netherlands.

Correspondence: *D Jonkers*, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands. E-mail: d.jonkers@maastrichtuniversity.nl. Phone: +31-043-3884266. Fax: +31-43-3874692.

**Key words:** acetaldehyde, colon, epithelial barrier, ethanol, fatty acid ethyl esters

doi:10.1111/nure.12027

Nutrition Reviews® Vol. 71(7):483–499

483

bowel syndrome.<sup>19</sup> Finally, decreased epithelial barrier function can result in increased susceptibility to carcinogens and may thereby contribute to the increased risk of alcohol-related cancers of the GI tract.<sup>20–23</sup>

Studies on the effects of ethanol intake on the intestinal epithelial barrier often focus on the small intestine, but ethanol and its metabolites can also reach the large intestine, depending on dosage, absorption, and metabolism.<sup>24</sup> Ethanol can be metabolized oxidatively and non-oxidatively, resulting in acetaldehyde, fatty acid ethyl esters (FAEEs), and phosphatidylethanol (PEth).<sup>25</sup> Many previous reviews have addressed the effects of ethanol and its main metabolite, acetaldehyde, on the GI tract, focusing on either carcinogenic effects or ALD. However, reviews on the effects of ethanol and all its (oxidative and nonoxidative) metabolites on small and large intestinal barrier function, as well as possible mechanisms of action, are limited.

This review aims to provide a broader understanding of the effects of ethanol and its oxidative and nonoxidative metabolites on intestinal barrier function. First, ethanol absorption and metabolism will be discussed, with a special focus on the GI tract. Subsequently, the effects of methanol and its metabolites on small and large intestinal barrier function, along with possible mechanisms of action, will be reviewed.

## ABSORPTION AND METABOLISM OF ETHANOL

Pharmacokinetic studies have shown large individual variations in the absorption, distribution, and elimination of ethanol.<sup>26,27</sup> After oral ingestion, ethanol is absorbed from the GI tract by simple diffusion due to its small molecular size, moderate lipid solubility, and excellent water solubility.<sup>28</sup> Minimal absorption occurs in the mouth and esophagus, and about 20% and 70% is absorbed through the stomach and the proximal small intestine, respectively, indicating that the majority of ingested ethanol is absorbed before it reaches the colon.<sup>29,30</sup> A small proportion of ethanol is excreted unchanged: 1–5% via the lungs, 0.1–0.5% in sweat, and 0.5–2% in urine.<sup>30,31</sup> The rate of ethanol absorption in the GI tract depends on several factors, including rate of gastric emptying, sex body mass index, presence of food in the stomach, and ethanol dosage and concentration.<sup>32,33</sup> After being absorbed, ethanol reaches the circulation and is rapidly distributed throughout the body fluids, with the rate of distribution related mainly to the water content of various tissues and organs.<sup>32</sup> Therefore, in the terminal ileum and colon, ethanol concentrations approximate those in blood.<sup>24,34,35</sup> In general, the body water content is lower in females, which contributes to higher blood ethanol concentrations in women than in men

after ingestion of similar doses per kilogram of body weight.<sup>36,37</sup>

## Oxidative metabolism of ethanol

Although the majority of absorbed ethanol (i.e., 90–98%) is metabolized in the liver, metabolism also occurs in the tissues of the GI tract, including the oral cavity, the esophagus, the stomach, and the small and large intestines.<sup>30,38–41</sup> Ethanol is metabolized oxidatively into acetaldehyde by alcohol dehydrogenase (ADH), which is located in the cytosol of hepatocytes, by the microsomal ethanol oxidizing system (MEOS) cytochrome P450 2E1 (CYP2E1) in the microsomes, and by catalase in the peroxisomes (Figure 1).<sup>25,30</sup> Of these, ADH is the main enzyme involved, and 10 isoenzymes (grouped into 5 classes) with varying kinetic properties, substrates specificities, and tissue distributions have been reported (Table 1).<sup>25,30,42–44</sup> Class I ADH enzymes (with a low  $K_m$ ) are highly expressed in the liver, but ADH expression has also been reported in intestinal epithelial cells, being higher in the villous tip than in the crypt region.<sup>45</sup> The mucosa of the oral cavity, esophagus, and stomach is characterized by a high expression of class IV ADH.<sup>46–48</sup> The esophagus has the highest ADH activity in the GI tract, similar to that of the liver and approximately four times that of the stomach.<sup>49</sup> In small and large intestinal mucosa, class I ADH is predominant, with a  $K_m$  of 1–2 mM for ethanol.<sup>39</sup> Interestingly, the activity of rectal ADH was found to be comparable to the activity of gastric ADH, suggesting that ethanol can be effectively metabolized to acetaldehyde in the rectal mucosa.<sup>40</sup> Evidence from both human and animal studies indicates that ethanol undergoes a first-pass metabolism in the stomach and liver, resulting in a significant decrease in the ethanol concentration reaching the blood.<sup>50</sup> An important role of the stomach is indicated by a clear decrease in first-pass metabolism after gastrectomy, after direct intraduodenal ethanol administration,<sup>51</sup> and in subjects with accelerated gastric emptying.<sup>33</sup> Gastric first-pass metabolism occurs predominantly by mucosal class IV ADH isoenzymes, especially  $\sigma$ -ADH.<sup>39,52–54</sup> The  $\sigma$ -ADH activity is lower in women than in men and, together with the lower body water content of women, contributes to the higher susceptibility of females to the injurious effects of ethanol.<sup>55–57</sup>

The CYP2E1-dependent MEOS, a pathway for ethanol metabolism that is present in several different cells, including hepatocytes, accounts for less than 10% of ethanol metabolism under normal conditions.<sup>58</sup> The MEOS becomes active only when high concentrations of ethanol ( $K_m$  7–10 mM) are present, and its activity is increased during chronic alcohol consumption.<sup>59</sup> It plays a key role in the pathogenesis of ethanol-related diseases




Figure 1 Oxidative ethanol metabolism in the liver cells (hepatocytes). Adapted from Zakhari.<sup>25</sup>

and carcinogenesis, as it potentiates the generation of free radicals and activates several xenobiotics, including carbon tetrachloride, to form potentially carcinogenic products.<sup>58,60</sup> Catalase is also able to oxidize ethanol, generating acetaldehyde and water in the presence of hydrogen peroxide ( $H_2O_2$ ).<sup>25</sup> Although catalase activity has been observed in human gastric and intestinal mucosae, no data from human studies in vivo are available on its role in ethanol metabolism.<sup>61</sup>

Acetaldehyde is rapidly metabolized in the liver and, to a lesser extent, in the oral cavity, esophagus, stomach, intestine, and pancreas via oxidation by aldehyde dehydrogenase (ALDH) into acetate (Figure 1).<sup>46,47</sup> Acetate is conjugated to form acetyl coenzyme A and is oxidized, mainly in the skeletal muscles, into  $CO_2$  and  $H_2O$ .<sup>62</sup> Thus far, 10 ALDH isoenzymes have been characterized (Table 2).<sup>63,64</sup> In addition to being expressed in the liver, class I ADH isoenzymes are also expressed in gastric

Table 1 Kinetic properties and tissue distribution of ADH isoenzymes.

Class	Gene	Protein	Km (mM)	$V_{max}$ ( $min^{-1}$ )	Tissue distribution
I	ADH1A	$\alpha$	4.0	30	Liver, small and large intestines
	ADH1B*1	$\beta_1$	0.05	4.0	Liver, lung, kidney
	ADH1B*2	$\beta_2$	0.9	350	Liver, lung, kidney
	ADH1B*3	$\beta_3$	40.0	300	Liver, lung, kidney
	ADH1C*1	$\gamma_1$	1.0	90	Liver, stomach
	ADH1C*2	$\gamma_2$	0.6	40	Liver, stomach
II	ADH4	$\pi$	30.0	20	Liver
III	ADH5	$\chi$	>1,000	100	Gingiva, tongue
IV	ADH7	$\sigma$ ( $\mu$ )	30.0	800	Liver, esophagus, stomach
V	ADH6		Unknown	Unknown	Liver, stomach

**Table 2 Distribution of ALDH isoenzymes among different body tissues and organs.**

Class	Gene	Allele	Tissue distribution
I	<i>ALDH1</i>	<i>ALDH1</i>	Liver, stomach, brain (cytosol)
II	<i>ALDH2</i>	<i>ALDH2*1</i>	Liver (mitochondrion)
		<i>ALDH2*2</i>	Liver, stomach (mitochondrion)
III	<i>ALDH3</i>	<i>ALDH3</i>	Stomach, lung, liver (cytosol)
IV	<i>ALDH4</i>	<i>ALDH4</i>	Liver, kidney (mitochondrion)
V	<i>ALDH5</i>	<i>ALDH5</i>	Testes, liver, brain, stomach (mitochondrion)
VI	<i>ALDH6</i>	<i>ALDH6</i>	Salivary gland, stomach (cytosol)
VII	<i>ALDH7</i>	<i>ALDH7</i>	Kidney, lung (microsomes)
VIII	<i>ALDH8</i>	<i>ALDH8</i>	Parotid gland (microsomes)
XI	<i>ALDH9</i>	<i>ALDH9</i>	Liver, kidney, muscle (cytosol)
X	<i>ALDH10</i>	<i>ALDH10</i>	Liver, heart (mitochondrion)

epithelial cells and in the small and large intestines. They possess a low  $K_m$  (0.6–4 mM) and a high maximal velocity. Therefore, they oxidize ethanol, even at low concentrations, at a constant rate.<sup>25,65</sup> Since mucosal ALDH activity is lower than ADH activity in the large intestine, accumulation of the reactive and toxic metabolite, acetaldehyde, is highly expected.<sup>41,66</sup>

Ethanol metabolism varies between different ethnic groups. For instance, the variant allele of ADH, *ADH1C\*1*, is more frequent in Asians than in Caucasians or Africans, and Asians metabolize ethanol more readily into acetaldehyde, resulting in accumulation of the latter.<sup>67,68</sup> In addition, the variant allele *ALDH2\*2*, which encodes an inactive subunit of the enzyme ALDH2, is dominant and highly prevalent (28–45%) in Asians but is rare in other ethnicities.<sup>65</sup> Homozygous carriers of the *ALDH2\*2* allele lack ALDH2 activity and consequently experience strong facial flushing and physical discomfort due to high blood acetaldehyde levels following ethanol consumption.<sup>69</sup> These adverse effects are less severe in heterozygous carriers, who have 10–50% of the ALDH2 activity seen in subjects who do not carry the *ALDH2\*2* allele, but heterozygous carriers are also at increased risk of developing ethanol-related GI cancers because they can metabolize only small amounts of acetaldehyde.<sup>69–71</sup>

Apart from those who consume large amounts of ethanol (>80 g daily) or engage in binge drinking (i.e., more than five drinks [>100 g] within 2 h), many people worldwide consume moderate amounts of alcohol (2 standard drinks) on a regular (i.e., at least weekly) basis.<sup>32,72</sup> Concentrations of ethanol after consuming two standard drinks (i.e., total of 28 g of ethanol) in luminal contents are found to be approximately 6.5–9.4 g/dL in the stomach, 6.5–9.4 g/dL in the jejunum, and 0.1–0.2 g/dL in the ileum as well as in the colon.<sup>24</sup>

### Nonoxidative metabolism of ethanol

While most studies have focused on oxidative metabolism, ethanol can also be metabolized nonoxidatively via

at least two pathways (Figure 2). First, ethanol may react with membrane phospholipids. Phospholipase D catalyzes transphosphatidylolation, thereby generating PEth, an abnormal phospholipid.<sup>25,73</sup> Since the PEth is not a normal constituent of membranes, it is poorly metabolized and, upon intracellular accumulation, disrupts the cell signaling that normally restricts proliferation in different tissues, including intestinal epithelial cells.<sup>74</sup> With a half-life of 4 days, PEth can be detected in blood and is considered a sensitive biomarker for both long-term and heavy ethanol consumption (>50 g/d) as well as for moderate alcohol consumption (40 g/d).<sup>75–79</sup> Furthermore, PEth has also been detected in rat small intestine<sup>80</sup> and human colonic tissue.<sup>74</sup> One hour after intake of ethanol (50–140 g/dL), serum PEth concentration has been found in the range of 45–138 ng/mL, reaching maximum concentrations of 74–237 ng/mL after between 3 days and 6 days.<sup>77</sup>

Secondly, ethanol may react with free fatty acids in a reaction catalyzed by fatty acid ethyl ester (FAEE) synthase<sup>25,73</sup> and cholesterol esterase,<sup>73,81</sup> generating FAEEs.<sup>73,82</sup> FAEEs can also be generated by transesterification of ethanol and fatty acyl-coenzyme A in a reaction catalyzed by acyl-coenzyme A: ethanol O-acyltransferase.<sup>73,83</sup> FAEEs have been detected in hair, heart, leukocytes, brain, adipose tissue, and meconium.<sup>84–90</sup> In the GI tract, FAEEs have been found to accumulate in the pancreas and the liver.<sup>91,92</sup> Since fatty acids and ethanol are absorbed by intestinal mucosa, the intestine is considered to be another site where FAEE synthesis can occur.<sup>83</sup> FAEE synthase activity with subsequent FAEE synthesis has been demonstrated in duodenal mucosa.<sup>83</sup> However, little is known about the concentrations of FAEEs present in the intestine after ethanol intake and their local effects on intestinal cell physiology. FAEEs have a half-life ranging between 16 h and 99 h and can therefore also be used as biomarkers for prior ethanol ingestion.<sup>93,94</sup> Ex vivo, inhibition of oxidative ethanol metabolism in the liver and pancreatic homogenates of rats by 4-methyl pyrazole, an ADH




Figure 2 Nonoxidative ethanol metabolism. Adapted from Zakhari<sup>25</sup> and Best and Laposata.<sup>73</sup>

inhibitor, by diallyl sulfide, an MEOS inhibitor, and by aminotriazole, a catalase inhibitor, has been shown to result in a shift toward the nonoxidative pathways, resulting in the generation of FFAEs.<sup>91</sup> Thus, a low ADH activity in chronic ethanol abusers may lead to accumulation of FFAEs and, consequently, increased risk for the injurious effects of FFAEs.<sup>95</sup>

### Role of microbiota in the endogenous production and oxidation of ethanol

In addition to being ingested orally, ethanol can be produced endogenously by bacterial fermentation of carbohydrates.<sup>96</sup> The endogenously produced ethanol is absorbed and transferred via the portal vein to the liver, where it is metabolized.<sup>97</sup> Although blood ethanol concentrations are usually very low in sober subjects (40–45 µg/dL), conditions associated with intestinal bacterial overgrowth, such as jejunoileal bypass surgery and tropical sprue, can lead to endogenous ethanol production of up to 1 mM (approximately 4.6 mg/dL) and of 2–31 mM (approximately 9.2–142.6 mg/dL) in blood and jejunal aspirates, respectively.<sup>98,99</sup> In addition, endogenously produced ethanol has also been found in the cecum of normally fed rats, with concentrations of 0.9 mM (4.14 mg/dL) reported.<sup>97</sup>

Several bacteria and yeasts can ferment sugars to ethanol,<sup>100</sup> including some that can be found in the GI

tract. For example, gastric overgrowth of *Helicobacter pylori*<sup>101</sup> and small intestinal overgrowth of coliform bacteria such as *Klebsiella pneumoniae*, *Enterobacter cloacae*, and *Escherichia coli* can contribute to endogenous ethanol production.<sup>98</sup> Coliform bacteria and, for example, *Clostridium* spp., may contribute to ethanol production in the colon as well.<sup>100</sup>

Endogenous and exogenous ethanol can also be further metabolized by the GI microbiota.<sup>102,103</sup> For instance, oral bacteria and yeasts, including *Streptococcus viridans*<sup>104</sup> and *Candida* strains,<sup>105</sup> and gastric bacteria such as *H. pylori*<sup>106</sup> have been found to possess ADH activity. Intestinal bacteria belonging to the Enterobacteriaceae family, such as *E. coli*, have also been shown to oxidize ethanol aerobically into acetaldehyde by an ADH-dependent reaction.<sup>107–109</sup> Furthermore, Salaspuro et al.<sup>108</sup> have demonstrated that *E. coli* is also able to convert ethanol into acetaldehyde under microaerobic, microaerophilic, and anaerobic conditions.

Several bacteria, such as members of the Enterobacteriaceae family, are known to possess catalase activity in addition to ADH activity. Tillonen et al.<sup>110</sup> demonstrated that human colonic contents could indeed generate acetaldehyde via catalase-dependent pathways.

Jokelainen et al.<sup>111</sup> have shown that in vitro incubation of human colonic contents with ethanol concentrations found in vivo can result in dose-dependent acetaldehyde production. Data on colonic luminal



acetaldehyde levels in humans are scarce, most likely due to the volatility of acetaldehyde, but some data from animal studies are available. A marked increase in mucosal acetaldehyde was found in rats with blind loops and concomitant bacterial overgrowth<sup>103</sup> as well as in the cecum and rectum of rats and the colon of pigs (271  $\mu$ M, approximately 1.2 mg/dL) after administration of 2.5–4.5 g/kg ethanol.<sup>112–115</sup> Furthermore, rectal mucosal acetaldehyde concentrations were found to be higher in conventional than in germ-free rats,<sup>112</sup> and cecal levels of acetaldehyde could be effectively reduced by pretreatment with ciprofloxacin,<sup>115</sup> pointing to a role of the intestinal microbiota in acetaldehyde production.<sup>112</sup>

Besides exhibiting ADH activity, facultatively anaerobic bacteria such as Enterobacteriaceae have also been found to exhibit ALDH activity.<sup>116</sup> However, the capacity of the intestinal microbiota to metabolize acetaldehyde by ALDH is rather low.<sup>117</sup> This, combined with the low levels of ALDH in colonic mucosa,<sup>118</sup> results in the accumulation of acetaldehyde in the large intestine.<sup>66</sup> Intracolonic production and accumulation of acetaldehyde is suggested to cause colorectal carcinogenesis<sup>119</sup> and to be an important determinant for blood acetaldehyde levels and subsequent hepatotoxicity.<sup>66</sup>

In summary, ethanol as well as its oxidative and non-oxidative metabolites can be found in the contents of both the small and the large intestines, either as a direct consequence of ethanol ingestion or via the systemic circulation, which involves the action of ethanol-metabolizing enzymes in the GI tract and microbiota.

### Ethanol-induced changes in the intestinal microbiota

Besides demonstrating the role of bacteria in ethanol metabolism, mounting evidence has shown that ethanol can also result in quantitative and qualitative changes in the intestinal microbiota. Yan et al.<sup>120</sup> have demonstrated in a mouse model that intragastric feeding of ethanol (30.9 g/kg per day) for 3 weeks induced small intestinal bacterial overgrowth and cecal dysbiosis. In rats, intragastric administration of ethanol (8 g/kg/d) for 10 weeks was shown to induce ileal and colonic dysbiosis.<sup>121</sup>

In humans, long-term ethanol consumption was found to be associated not only with small intestinal bacterial overgrowth<sup>122,123</sup> but also with alterations in the composition of the mucosa-associated microbiota in sigmoid biopsies.<sup>124</sup> Mutlu et al.<sup>124</sup> found a lower abundance of Bacteroidetes and a higher abundance of Proteobacteria in alcoholics than in healthy controls. In a randomized crossover study performed in healthy volunteers who consumed red wine, dealcoholized red wine, or gin for 20 days, all interventions resulted in changes in the fecal microbiota, as demonstrated by

quantitative PCR and denaturing gradient gel electrophoresis, with changes differing among groups.<sup>125</sup> In line with the above, a reduction in the proportion of Bacteroidetes and an increase in the Proteobacteria were also demonstrated by 454 pyrosequencing in a mixed group of patients with hepatitis-B or ethanol-related liver cirrhosis versus healthy individuals. Furthermore, the authors also reported changes on the family level, including, for example, increased numbers of Enterobacteriaceae and Streptococcaceae and reduced numbers of Lachnospiraceae.<sup>126</sup> Moreover, probiotic and synbiotic interventions have been demonstrated to attenuate liver injury in a rat model of alcoholic steatohepatitis<sup>127</sup> and liver dysfunction in cirrhotic patients,<sup>128</sup> respectively, supporting a role for the gut microbiota in ethanol-induced liver diseases.

In addition to possibly enhanced translocation of endotoxins and direct effects of bacteria on the epithelial barrier, alterations in the composition and activity of gut microbiota can also result in changes in the production or breakdown of ethanol and acetaldehyde. In an in vitro study, for example, Nosova et al.<sup>129</sup> demonstrated that *Bifidobacterium* spp. and, to a greater extent, *Lactobacillus* GG, are weak acetaldehyde generators but have a high acetaldehyde-metabolizing capacity, which correlates positively with bacterial concentrations. Nevertheless, additional data on the effects of different dosages and durations of ethanol intake on the intestinal microbiota and subsequent ethanol-related microbial metabolic activity in humans are warranted.

## EPITHELIAL BARRIER DISRUPTION MEDIATED BY ETHANOL AND ITS METABOLITES

### Intestinal epithelial barrier

The GI epithelium is composed of a continuous monolayer of intestinal epithelial cells, which facilitate a selective passive entry of luminal nutrients, ions, and water while restricting access of pathogenic substances and microorganisms by means of transcellular and paracellular pathways.<sup>130</sup> The transcellular pathway contains lipophobic and lipophilic pores located in the brush border membrane of enterocytes.<sup>131</sup> The paracellular pathway is regulated via apical intercellular junctional proteins known as tight junctions (TJs) and via associated proteins known as the adherens junctions (AJs).<sup>131</sup> The TJs are composed of transmembrane proteins (e.g., claudins), integral membrane proteins (e.g., occludin), junction adhesion molecules, and cytoplasmic zona occludens (ZO) proteins (e.g., ZO-1, ZO-2, and ZO-3), which connect the TJ complex intracellularly with the actin cytoskeleton.<sup>132</sup> The TJs are regulated by both intra- and

extracellular signaling molecules. Intracellular signaling molecules that regulate the assembly and disassembly of the TJs include, for example, myosin light chain kinase (MLCK),<sup>133</sup> Rho GTPases,<sup>134</sup> protein kinase C,<sup>135</sup> mitogen-activated protein kinases,<sup>136</sup> protein tyrosine kinase,<sup>137</sup> intracellular calcium,<sup>138</sup> and zonulin.<sup>139,140</sup> Extracellular modulators of the TJs include, for example, nutrients, xenobiotics such as nonsteroidal anti-inflammatory drugs, and cytokines (e.g., interferon- $\gamma$ , tumor necrosis factor- $\alpha$ , and interleukin-1 $\beta$ ).<sup>141–145</sup> Intestinal epithelial barrier function in vivo can be assessed noninvasively by measuring ingested test probes (sugars, polyethylene glycol, radioactively labelled chromium-EDTA), analyzing TJ structures, or measuring the sequelae of barrier dysfunction, such as bacterial translocation and production of serum/plasma endotoxins.<sup>146–149</sup>

### Effects of ethanol on small and large intestinal barrier function

Ethanol and its oxidative and nonoxidative metabolites can be found throughout the GI tract, where they can interfere with several functions, including those of the intestinal barrier. It has been shown that, after oral administration of 0.8 g/kg ethanol as a 25% solution, luminal levels of ethanol can reach more than 400 mg/dL and can be maintained for 60 min in the stomach, in the proximal jejunum, and in the duodenum, whereas levels in the ileum were approximately 200 mg/dL, parallel to those in blood.<sup>24</sup> Ethanol concentrations found in the colon are comparable to those in blood.<sup>24,34,35</sup> Hence, the continuous presence of ethanol in the GI tract, which results from equilibration throughout the vascular space, may account for the ethanol-induced epithelial barrier dysfunction in both the upper and the lower GI tract. Few studies have investigated the effects of ethanol intake on GI tract barrier function in humans (Table 3). Most studies are performed in long-term ethanol abusers, defined as individuals with a consumption of more than four drinks (>80 g alcohol) per day,<sup>32</sup> the majority of whom are also diagnosed with ALD. Overall, an increase in small intestinal permeability was observed in long-term ethanol abusers (alcoholics)<sup>9,10,14,150–153</sup>; likewise, gastroduodenal permeability increased in nonalcoholics following administration of a single dose of ethanol.<sup>151,154</sup> Millan et al.<sup>155</sup> reported histological changes in the small intestine following administration of a single dose of ethanol in nonalcoholics, although barrier function was not assessed. Hirsch et al.<sup>150</sup> did not find changes in the permeability of the small intestine of long-term abusers after 3 days of abstinence. However, in a similar group of patients, the ethanol-induced increase in gastroduodenal permeability was found to persist for at least 7 days in the presence of aspirin.<sup>152</sup> In patients with ALD, an increase in

small intestinal permeability has been found to be associated with high levels of endotoxins in blood.<sup>9,14,156,157</sup> Animal studies have demonstrated that both short- and long-term ethanol administration, at dosages ranging from 6 g/kg/day to 8 g/kg/day, can increase intestinal permeability and induce endotoxemia,<sup>12,13,15,158</sup> subsequently leading to liver injury,<sup>12,13,15</sup> intestinal inflammation,<sup>159</sup> and rectal carcinogenesis.<sup>112,160,161</sup> Moreover, ethanol, when present along with alterations in intestinal permeability and immune status, has been shown to lead to small intestinal bacterial overgrowth, contributing to an increase in endotoxin translocation and an exacerbation of intestinal tissue damage after burn injury in rats.<sup>162,163</sup> Data from studies in humans have confirmed that small intestinal bacterial overgrowth can also occur in patients with ALD, in whom increased numbers of aerobic and anaerobic bacteria were found in jejunal aspirates.<sup>122,123</sup> Data on the effects of ethanol on human colonic barrier function are lacking. In animals, oral administration of ethanol (3–4.5 g/kg) in rats as well as ex vivo exposure of rat colon to acetaldehyde (40–160  $\mu$ M, approximately 176–704  $\mu$ g/dL) resulted in increased colon permeability.<sup>164</sup> Antibiotics and doxantrazole, a mast cell membrane stabilizer, significantly inhibited these effects, pointing to a mechanistic role for the enteric microbiota and mast cell activation.<sup>164</sup> As for human data, it has recently been shown that moderate red wine consumption can increase small intestine and colon permeability in patients with inflammatory bowel disease.<sup>154</sup>

### In vitro studies on the effects of ethanol and acetaldehyde on epithelial integrity

The majority of data on ethanol-induced barrier dysfunction results from in vitro studies, all using Caco-2 cell monolayers. It was found that ethanol in concentrations of 0.1% up to 10% (92–920 mg/dL) significantly decreased transepithelial electrical resistance and increased permeation markers (see Table 4). In two studies, ethanol up to a 5% (4.6 g/dL) concentration failed to increase paracellular permeability.<sup>165,166</sup> In contrast, ethanol at concentrations of 2.5% (2.3 g/dL) and above has been shown to increase paracellular permeability by compromising the cell viability.<sup>167,168</sup> Ethanol metabolism into acetaldehyde has been suggested to be required for ethanol-induced barrier disruption. Indeed, acetaldehyde at concentrations ranging from 25  $\mu$ M to 760  $\mu$ M (0.11–3.3 mg/dL) has also been demonstrated to increase permeability (see Table 5). The concentrations of ethanol tested in vitro were comparable to those found in the human upper GI tract,<sup>24</sup> whereas concentrations of acetaldehyde were comparable to those found in the rat colon (0.12–3 mM, approximately 0.53–13.2 mg/dL).<sup>169</sup>

Table 3 Human studies exploring the effect of ethanol consumption on intestinal barrier function.

Subjects	Dose of ethanol (route of administration)	Parameters assessed	Major findings	Reference
Nonalcoholics ( <i>n</i> = 20)	45 g or 60 g (single intragastric dose)	Histological changes	Transient damage to the upper small intestine	Millan et al. <sup>155</sup>
Nonalcoholics ( <i>n</i> = 12)	20 g (single oral dose)	Intestinal permeability by PEG	Reversible altered permeability in alcoholics and nonalcoholics	Robinson et al. <sup>10</sup>
Alcoholics ( <i>n</i> = 12)	>80 g/day for >5 yrs	Intestinal permeability by chromium-51-EDTA	Increased intestinal permeability in alcoholics > nonalcoholics	Bjarnason et al. <sup>9</sup>
Nonalcoholics (15)	>80–150 g/day for >3 yrs	Blood endotoxin levels	Increased endotoxin levels in patients with cirrhosis > patients without cirrhosis	Bode et al. <sup>156</sup>
Alcoholics ( <i>n</i> = 36)	>80–150 g/day for >3 yrs			
Alcoholics with cirrhosis ( <i>n</i> = 88)	>80 g/day for ≥5 yrs			
Alcoholic without cirrhosis ( <i>n</i> = 42)	>80 g/day for ≥5 yrs			
Nonalcoholics ( <i>n</i> = 20)	0.8 g/kg (oral, i.v.)	Intestinal permeability by morphological changes	Increased gastroduodenal permeability in alcoholics.	Keshavarzian et al. <sup>151</sup>
Alcoholics ( <i>n</i> = 18)	100 g/day for ≤5 yrs		Reversible changes in villous integrity in alcoholics	
Nonalcoholics ( <i>n</i> = 10)	Nondrinkers	Intestinal permeability by lactulose-mannitol test	Increased intestinal permeability in alcoholics with chronic liver disease	Keshavarzian et al. <sup>157</sup>
Alcoholics ( <i>n</i> = 18)	100 g/day for ≤5 yrs			
Nonalcoholics ( <i>n</i> = 18)	Undefined	Intestinal permeability by lactulose-mannitol test on the third day of abstinence	No changes in intestinal permeability	Hirsch et al. <sup>150</sup>
Alcoholics ( <i>n</i> = 19)	Undefined			
Nonalcoholics ( <i>n</i> = 30)	Nondrinkers	Intestinal permeability by PEG and blood endotoxin levels	Increased intestinal permeability and endotoxin levels in ALD patients (with or without cirrhosis)	Parlesak et al. <sup>14</sup>
Alcoholics with ( <i>n</i> = 19) or without cirrhosis ( <i>n</i> = 35)	>60 g/day for >3 yrs			
Nonalcoholics ( <i>n</i> = 26)	>60 g/day for >3 yrs	Intestinal permeability by PEG 400 and PEG 3350	Increased intestinal permeability in patients with cirrhosis and ascites	Lee et al. <sup>153</sup>
Alcoholics with cirrhosis ( <i>n</i> = 35)	Undefined	Intestinal permeability by lactulose-mannitol-sucralose test	Increased small intestinal and colon permeability in patients with CD and UC	Swanson et al. <sup>154</sup>
Healthy subjects ( <i>n</i> = 7)	0.4 g ethanol/kg (oral)			
Patients with CD ( <i>n</i> = 6)	0.4 g ethanol/kg (oral)			
Patients with UC ( <i>n</i> = 8)	0.4 g ethanol/kg (oral)			

Abbreviations: ALD, alcoholic liver disease; CD, Crohn's disease; PEG, polyethylene glycol; UC, ulcerative colitis.



**Table 4 In vitro studies exploring the effects of ethanol on paracellular permeability using Caco-2 cell monolayers.**

Ethanol concentration <sup>a</sup> / exposure time	Significant findings	Possible mechanisms	Reference
1%, 2.5%, 5%, 7.5%, 10%	Dose-related drop in TEER Increase in FSA permeability Disruption of TJ integrity Displacement of actin and myosin filaments	MLCK activation	Ma et al. <sup>166</sup>
0–15%	Increase in FSA permeability Disassembly of the microtubules	Oxidative stress	Banan et al. <sup>167</sup>
0–2.5%/24 h	Increase in FSA permeability Disruption of F-actin	NF-kappaB activation	Banana et al. <sup>187</sup>
5%/5 h	Drop in TEER Increase in FSA permeability Decrease in ZO-1, occludin, and claudin-1 protein levels	Zinc deficiency Oxidative stress	Zhong et al. <sup>198</sup>
5%/24 h	Drop in TEER Increase in FITC-D4 permeability Decrease in occludin protein levels	HNF-4 $\alpha$ inactivation via oxidative stress and zinc deficiency	Zhong et al. <sup>191</sup>
0.1% and 1%/3 h	Drop in TEER Increase in FITC-D4 permeability Decrease in occludin protein levels	Induction of miR-212 expression with subsequent decrease in ZO-1 translation	Tang et al. <sup>192</sup>
0.2%/2 h	Drop in TEER Increase in FITC-D4 permeability Decrease in occludin protein levels	Stimulation of intestinal circadian clock gene expression	Swanson et al. <sup>190</sup>
0.2%/2 h	Drop in TEER Increase in FSA permeability Increase in p-Snail protein levels	iNOS- mediated ethanol-induced Snail activation	Forsyth et al. <sup>193</sup>
0.1–1%/3 h	Increase in FITC-D4 permeability Disruption of ZO-1 and occludin integrity Increase in acetylated microtubule protein levels	Hyperacetylation of microtubules	Elamin et al. <sup>194</sup>

<sup>a</sup> 1% equals 1 g/dL.

**Abbreviations:** FITC-D4, fluorescein isothiocyanate-labeled dextran 4 kD; FSA, fluorescein-5-(and-6)-sulfonic acid trisodium salt; HNF-4 $\alpha$ , hepatocyte nuclear factor-4 $\alpha$ ; iNOS, inducible nitric oxide synthase; MLCK, myosin light chain kinase; PER2, period circadian protein homolog 2; TEER, trans-epithelial electrical resistance; ZO-1, zona occludens 1.

### MECHANISMS OF INTESTINAL BARRIER DYSFUNCTION INDUCED BY ETHANOL AND ITS METABOLITES

Several mechanisms underlying the ethanol-induced barrier dysfunction have been proposed, including direct damage to epithelial cells, loss of integrity of TJs and/or AJs, and changes in intestinal microbiota, each of which is discussed below.

#### Direct damage to epithelial cells

Ethanol and its metabolites can induce direct cell injury. Long-term ethanol ingestion has been reported to induce ultrastructural and histological changes in duodenal mucosa, including a decrease in the mean total mucosal surface area in chronic alcoholics.<sup>170</sup> Data on the effects of long-term moderate intake are not known. However, oral ingestion of a single dose of ethanol (1 g/kg, administered

as a 35 g/dL solution) has been shown to result in histological changes in the duodenum, including subepithelial bleb formation, hemorrhagic erosions, and inflammatory cell infiltration.<sup>171</sup> In the rectal mucosa of individuals who consumed excessive amounts of ethanol, several ultrastructural changes were found, including inflammatory changes, a decreased number of mucin-secreting goblet cells, and alterations in cell organelles such as distorted mitochondria and dilated endoplasmic reticulum.<sup>172</sup>

Animal studies have demonstrated that acute intragastric administration of ethanol at 5–20% (4.6–18.4 g/dL) for 4 h can result in hemorrhagic erosions and epithelial cell loss in the proximal small intestine of rats.<sup>173</sup> Similar lesions have also been found in rats gavage fed for 14 days with 18.4 g/dL ethanol, including exfoliation and subepithelial edema of villous tips.<sup>174</sup> Administration of a single dose of ethanol (6 g/kg) in mice has also been demonstrated to induce severe injury in ileal

**Table 5** In vitro studies exploring the effects of acetaldehyde on paracellular permeability using Caco-2 cell monolayers.

Exposure concentration/time	Significant findings	Possible mechanisms	Reference
100–760 $\mu$ M/4 h	Reduction of TEER Increase in mannitol permeability	–	Rao <sup>165,182</sup>
650 $\mu$ M/6 h	Decrease in TEER Increase in inulin permeability Tyrosine phosphorylation of ZO-1, E-cadherin, and $\beta$ -catenin	Inhibition of protein tyrosine phosphatases	Atkinson & Rao <sup>137</sup>
100–600 $\mu$ M/4 h	Decrease in TEER Increase in inulin and endotoxin permeability Dissociation of ZO-1, occludin, E-cadherin, and $\beta$ -catenin	–	Seth et al. <sup>183</sup>
100–600 $\mu$ M/4 h	Decrease in TEER Increase in inulin and endotoxin permeability Reorganization of occludin, ZO-1, E-cadherin, and $\beta$ -catenin Reorganization of actin cytoskeleton	–	Sheth et al. <sup>184</sup>
100–600 $\mu$ M/3–6 h	Redistribution of and reduction in ZO-1, occludin, E-cadherin, and $\beta$ -catenin protein levels Protein tyrosine phosphorylation	Inhibition of protein tyrosine phosphatases	Basuroy et al. <sup>186</sup>
400 $\mu$ M/0.5 h	Redistribution of E-cadherin and $\beta$ -catenin Tyrosine phosphorylation of $\beta$ -catenin Abolishment of interaction of $\beta$ -catenin with E-cadherin	Tyrosine kinase activation	Sheth et al. <sup>185</sup>
100–760 $\mu$ M/5 h	Decrease in TEER Increase in inulin permeability Redistribution of ZO-1, occludin, E-cadherin, and $\beta$ -catenin. Reorganization of actin cytoskeleton Tyrosine phosphorylation of occludin, ZO-1, claudin-3, and E-cadherin	Tyrosine kinase activation	Samak et al. <sup>136</sup>
25–100 $\mu$ M/3 h	Increase in FITC-D4 permeability. Disruption of ZO-1 and occludin integrity. Increase in acetylated microtubule protein levels	Hyperacetylation of microtubules	Elamin et al. <sup>194</sup>

Abbreviations: FITC-D4, fluorescein isothiocyanate-labeled dextran 4; TEER, trans-epithelial electrical resistance; ZO-1, zona occludens 1.

mucosa, including formation of submucosal blebbing and ulceration of microvilli.<sup>15</sup>

Long-term (16 weeks) ethanol administration induced various alterations in rat enterocytes, including enlargement, dilatation, and diminishment of the mitochondria, the smooth endoplasmic reticulum, and the rough endoplasmic reticulum, respectively.<sup>175</sup> Interestingly, these alterations were more prominent in the distal ileum than in the proximal jejunum, pointing to the bloodborne route of ethanol in inducing such effects rather than a first-pass effect on the ileal mucosa.<sup>175</sup>

Apart from the histological observations, most data on epithelial cell damage as well as further mechanistic insight come from in vitro experiments. In vitro studies using Caco-2 cell monolayers have shown that luminal (i.e., apical) exposure to high ethanol concentrations (i.e., 10–15%, approximately 9.2–13.8 g/dL) can decrease cell viability.<sup>166,167</sup> Ethanol at 13.8 g/dL has been found to induce cell apoptosis, an effect that was synergistically

enhanced in the presence of estradiol, pointing to a possibly more severe effect of ethanol in females.<sup>7,176</sup> Low concentrations (i.e., <1%, <0.92 g/dL) have been shown to promote Caco-2 cell differentiation and to synergize with *E. coli* to induce cell apoptosis.<sup>177,178</sup> Studies investigating effects of acetaldehyde on intestinal cytotoxicity are scarce. However, at concentrations  $\leq 1,000 \mu$ M ( $\leq 0.44$  g/dL), acetaldehyde has not been found to compromise intestinal cell viability.<sup>179</sup> Further studies investigating wider ranges of concentrations are warranted.

Nonoxidative ethanol metabolites such as palmitoleic and palmitic acid ethyl esters (10–100  $\mu$ M) have also been demonstrated to induce pancreatic acinar cell necrosis through mechanisms involving intracellular calcium release.<sup>180</sup> It has also been shown that FAEs at concentrations (20–40  $\mu$ M) reached in blood after moderate ethanol consumption can induce oxidative stress and decrease mitochondrial function in intestinal epithelial cells without compromising cell viability.<sup>181</sup> The

discrepancy between recent data and data from earlier studies can be explained by differences in cell type, dosage of ethanol, and duration of exposure to FAEs. Data on the cell-damaging effects of PEth on intestinal epithelial cells are not available. Therefore, further study is required to determine the exact role of PEth and FAEs in ethanol-induced intestinal epithelial damage.

### Effects on tight junction integrity

**Ethanol.** The main mechanisms by which ethanol and its metabolites result in barrier dysfunction are through direct and indirect effects on the integrity of TJs (Table 4). Interactions between AJ proteins (E-cadherin and  $\beta$ -catenin), TJ proteins (ZO-1 and occludin), and cytoskeletal proteins are crucial for the organization of the TJ complex and for subsequent maintenance of the intestinal epithelial barrier.<sup>137,182–186</sup> Several mechanisms involving ethanol-induced disruption of epithelial TJs and AJs have been identified. Ma et al.<sup>166</sup> have shown that ethanol (1–10%, approximately 0.92–9.2 g/dL) in Caco-2 monolayers can reversibly disrupt the intestinal epithelial TJ integrity through MLCK activation and subsequent modulation of perijunctional actin and myosin filaments. Furthermore, incubation of Caco-2 cells with ethanol (2.5%, approximately 2.3 g/dL) for 24 h has been shown to induce nuclear factor- $\kappa$ B activation, thereby resulting in F-actin cytoskeleton instability and, consequently, intestinal barrier dysfunction.<sup>187</sup> Ethanol has also been found to affect intestinal cells by targeting a number of pre- and post-transcriptional regulators, including circadian clock genes and microRNA (miRNA; short ribonucleic acid molecules of an average of 22 nucleotides that bind to complementary sequences on target messenger RNA transcripts, resulting in translational repression), respectively.<sup>188,189</sup> Swanson et al. have demonstrated in the rat duodenum and proximal colon as well as in Caco-2 cells that ethanol-induced intestinal barrier dysfunction occurs through mechanisms involving upregulation of intestinal circadian clock gene expression.<sup>190</sup> In addition, in Caco-2 monolayers, ethanol downregulated the target gene ZO-1 of miRNA-212 and, consequently, decreased the mRNA and protein levels of ZO-1 through a mechanism involving hepatocyte nuclear factor-4 $\alpha$  dysfunction.<sup>191,192</sup> In addition, ethanol has been found to induce activation of one of the transcription factors involved in an epithelial-mesenchymal transition program, known as Snail, resulting in upregulation of inducible nitric oxide synthase (iNOS) and, consequently, intestinal epithelial hyperpermeability.<sup>193</sup> Ethanol is also able to induce post-translational modifications in intestinal cell proteins. Very recently, it was demonstrated in a three-dimensional Caco-2 cell culture model that basal exposure to ethanol (40 mM,

approximately 184 mg/dL) for 3 h can induce microtubule hyperacetylation, resulting in redistribution of ZO-1 and, consequently, loss of TJ integrity.<sup>194</sup> Such effects were independent of altered TJ-encoding gene expression.

A large number of studies have investigated the role of oxidative stress on the intestinal mucosa as a possible mechanism to explain barrier dysfunction. There is strong evidence to indicate the involvement of cellular oxidative stress in mediating ethanol-induced intestinal barrier dysfunction.<sup>195</sup> Evidence provided by Banan et al.<sup>167,196</sup> has shown that ethanol (2.5–15%, approximately 2.3–13.8 g/dL) can increase the paracellular permeability of Caco-2 monolayers via iNOS-mediated generation of reactive oxygen species (ROS), resulting in oxidation of the microtubule cytoskeleton and, consequently, disassembly of the TJs. The involvement of iNOS in ROS-mediated ethanol-induced intestinal hyperpermeability has been confirmed in rats gavaged with ethanol (6 g/kg/day) for 10 weeks. In that study, inhibition of iNOS attenuated ethanol-induced gut leakiness and the associated endotoxemia.<sup>197</sup> Moreover, decreased intestinal antioxidant capacity has been found to play a crucial role in ethanol-induced intestinal disruption. Zhong et al.<sup>198</sup> demonstrated in mice that long-term ethanol (4.8%, approximately 4.4 g/dL) gavage for 4 months can induce ileal oxidative stress mediated by zinc deficiency, thereby sensitizing epithelial cells to ethanol, resulting in loss of TJ integrity.

**Acetaldehyde.** Evidence from in vitro and an ex vivo studies revealed that acetaldehyde has a higher potency than ethanol to induce intestinal barrier dysfunction,<sup>164,165,182</sup> thereby highlighting the relevance of this oxidative metabolite. Mechanistic studies have demonstrated in Caco-2 monolayers that acetaldehyde can induce redistribution of occludin and ZO-1 from the intercellular junctions into the intracellular compartments,<sup>137,183–185</sup> leading to dissociation of these proteins from the actin cytoskeleton, resulting in paracellular hyperpermeability.<sup>186,199</sup> Acetaldehyde not only disrupts the TJs but also induces redistribution of E-cadherin and  $\beta$ -catenin, thereby disrupting the integrity of the AJs.<sup>137,185</sup> The role of several cell-signaling pathways that regulate barrier function, including protein tyrosine kinases<sup>200–204</sup> and protein tyrosine phosphatases,<sup>203</sup> in acetaldehyde-induced loss of TJ integrity has been explored. Basuroy et al.<sup>186</sup> have demonstrated that acetaldehyde induces tyrosine phosphorylation and disrupts the integrity of TJs and AJs in human colonic mucosa. Sheth et al.<sup>184</sup> have shown that acetaldehyde can induce protein tyrosine phosphorylation of E-cadherin and  $\beta$ -catenin, resulting in loss of interaction between these proteins and, consequently, barrier dysfunction. In

addition, acetaldehyde-induced inhibition of protein tyrosine phosphatase was found to disrupt the interactions between the AJ proteins and protein tyrosine phosphatase 1B and, consequently, to induce paracellular barrier dysfunction in vitro<sup>137</sup> and in human colon ex vivo.<sup>186</sup> Not only protein phosphorylation but also hyperacetylation can interfere with barrier dysfunction. Recently, in a three-dimensional Caco-2 cell culture model, it was demonstrated that exposure to acetaldehyde (25  $\mu$ M, approximately 110  $\mu$ g/dL) for 3 h can result in increased paracellular permeability through mechanisms involving hyperacetylation of microtubular protein ( $\alpha$ -tubulin).<sup>194</sup>

**Nonoxidative metabolites.** Data on the effects of the non-oxidative metabolites, i.e., PETH and FAEEs, on the intestinal epithelial barrier function are limited. In one study, incubation of Caco-2 cells for 48 h with ethanol (0.05%, 46 mg/dL) was found to increase intracellular accumulation of PETH, resulting in claudin-1 endocytosis, disruption of claudin-1/ZO-1 TJs, and activation of ZO-1-associated nucleic acid binding proteins (ZONABs), which, consequently, promoted cell proliferation.<sup>74</sup> Similarly, high levels of accumulated PETH in colonic polyp sections obtained from long-term ethanol abusers were associated with remarkable ZO-1 mislocalization.<sup>74</sup> These data have been confirmed in vivo and ex vivo; for example, incorporation of PETH in membranes and disruption of ZO-1 and ZONAB localization was found to be correlated with increased cell proliferation in the colonic epithelium of mice (consuming 9.2 g/dL for 4 months) and in the adenomas of long-term ethanol consumers (30 g/d), respectively.<sup>74</sup> Although FAEEs have been found to possess cytotoxic activity in pancreatic cells<sup>205,206</sup> and liver cells,<sup>207</sup> research on their role in ethanol-induced barrier dysfunction has received little attention. However, it was recently shown in a Caco-2 three-dimensional cell culture model that exposure to ethyl ester oleate and ethyl ester palmitate at 20  $\mu$ M or 40  $\mu$ M concentrations can dose dependently induce ZO-1 and occludin redistribution and, consequently, a decrease in the paracellular barrier function.<sup>181</sup> Interestingly, these changes were partially attenuated by preincubation with the nutritional antioxidant resveratrol, pointing to the involvement of ROS generation in FAEE-induced intestinal barrier dysfunction.<sup>181</sup>

### Modulation of tight junctions by microbiota

In addition to converting ethanol into acetaldehyde metabolically,<sup>66</sup> the intestinal microbiota can also modulate the TJs directly or indirectly via increased levels of lipopolysaccharide (LPS), an endotoxin derived from gram-negative bacteria.<sup>208</sup> As discussed previously, ethanol has

been shown to alter the composition of the intestinal microbiota, which can result in increased levels of endotoxin.<sup>124</sup> Bode et al.<sup>122</sup> showed that ethanol can induce overgrowth of gram-negative anaerobic bacteria in the jejunum of alcoholics, predisposing them to increased levels of luminal LPS. Furthermore, short-term ethanol administration has been shown to increase plasma LPS levels approximately fivefold within 30–90 min in rats<sup>209</sup> and in mice,<sup>210</sup> whereas 4 weeks of ethanol feeding increases the plasma LPS levels 15-fold in rats.<sup>211</sup> In humans, long- and short-term ethanol consumption has been found to induce excessive and transient increases in blood LPS levels, respectively.<sup>122,212,213</sup> LPS has been shown to induce epithelial hyperpermeability via a poly (ADP-ribose) synthetase (PARS)-dependent mechanism<sup>214</sup> and MLCK activation.<sup>215</sup> Since increased levels of circulating LPS can potentiate an increase in intestinal permeability,<sup>208</sup> ethanol and LPS in combination may represent a two-hit insult on intestinal epithelial barrier integrity.

Intestinal bacteria can also modulate intestinal barrier integrity directly via mechanisms involving changes in TJ protein expression and distribution. The effects differ between bacterial strains. For example, enteropathogenic *E. coli* has been demonstrated to disrupt TJs in vitro<sup>216</sup> and to increase intestinal epithelial permeability in vivo.<sup>217</sup> In contrast, several probiotic bacteria, including *E. coli* strain Nissle 1917,<sup>218,219</sup> *Bifidobacterium infantis*,<sup>220</sup> and *Lactobacillus plantarum* MB452,<sup>221</sup> have been shown to promote intestinal barrier integrity in vitro by increasing expression of the ZO-2 and occludin proteins, by reducing expression of the claudin-2 protein, and by increasing transcription of the occludin genes. Furthermore, Karczewski et al.<sup>222</sup> have recently shown that administration of *Lactobacillus plantarum* WCFS1 into the duodenum of healthy human volunteers increases expression of ZO-1 and occludin in duodenal biopsies and protects against phorbol ester-induced dislocation of ZO-1 and occludin in vitro.

Studies investigating the role of the intestinal microbiota in ethanol-induced intestinal barrier dysfunction have been performed in rats and have reported that pretreatment with antibiotics can ameliorate ethanol-induced intestinal barrier dysfunction and the associated endotoxemia.<sup>164,223</sup> Modulation of gut microbiota by probiotics or prebiotics<sup>13,224</sup> in animals<sup>127,225</sup> and in humans<sup>226</sup> has been demonstrated to improve the intestinal barrier function. Therefore, the effects of probiotic or prebiotic treatment on intestinal barrier function after moderate and long-term ethanol consumption merit further investigation.

### CONCLUSION

On the basis of currently existing knowledge, ethanol and its metabolites, including acetaldehyde, PETH, and FAEEs,



are considered to reach the entire GI tract, including the large intestine. The effects of ethanol and its metabolites on the intestine depend on various factors such as the food consumption pattern and host factors, e.g., sex, and the presence of gene polymorphisms for the enzymes involved in ethanol metabolism. Although ethanol by itself can be injurious, scientific evidence strongly points towards a very important role of its oxidative metabolite acetaldehyde, especially in intestinal barrier disruption and induction of colorectal cancers associated with ethanol consumption. In addition, ethanol has been shown to act synergistically with acetaldehyde, *E. coli*, and burn injury, resulting in more pronounced intestinal barrier dysfunction.

In vitro studies have led to exciting new information on the mechanisms of ethanol- and acetaldehyde-induced TJ disruption. However, detailed information about the precise mode of interaction between the TJ proteins complex and the mechanisms by which this TJ disruption can be (therapeutically) modulated or prevented is still lacking. So far, information on the effects of the nonoxidative metabolites, i.e., PETH and FAEs, on intestinal epithelial barrier function is limited and has received little attention. The evidence so far, however, indicates that nonoxidative metabolites could be major modulators of epithelial permeability. Moreover, information on the effects of ethanol and acetaldehyde on other components of intestinal epithelium, such as mucin and mucin-secreting cells (i.e., goblet cells), is largely lacking. Since the intestinal microbiota plays a crucial role in the generation and accumulation of intracolonic acetaldehyde, and since ethanol and its metabolites can reach the colon via blood, mechanistic research on ethanol-induced colonic barrier dysfunction, taking into account the role of the gut microbiota, is warranted. Understanding the cellular and molecular mechanisms that mediate the effects of ethanol and its metabolites on intestinal barrier dysfunction may provide leads for therapeutic targets that can prevent or reverse ethanol-induced intestinal failure and subsequent liver injury.

## Acknowledgments

**Funding.** This study was funded by Top Institute Food and Nutrition, Wageningen, The Netherlands.

**Declaration of interest.** The authors have no relevant interests to declare.

## REFERENCES

- World Health Organization. *WHO Global Status Report on Alcohol 2004*. Geneva: Department of Mental Health and Substance Abuse, World Health Organization; 2004.
- Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. *Alcohol Res Health*. 2003;27:209–219.
- Saunders JB, Latt N. Epidemiology of alcoholic liver disease. *Baillieres Clin Gastroenterol*. 1993;7:555–579.
- Deltenre P, Mathurin P. [Epidemiology of alcoholic liver disease and new challenges] [in French]. *Gastroenterol Clin Biol*. 2009;33:1147–1150.
- Salaspuuro MP. Alcohol consumption and cancer of the gastrointestinal tract. *Best Pract Res Clin Gastroenterol*. 2003;17:679–694.
- Robles EA, Mezey E, Halsted CH, et al. Effect of ethanol on motility of the small intestine. *Johns Hopkins Med J*. 1974;135:17–24.
- Asai K, Buurman WA, Reutelingsperger CP, et al. Low concentrations of ethanol induce apoptosis in human intestinal cells. *Scand J Gastroenterol*. 2003;38:1154–1161.
- Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. *Hepatology*. 2009;50:638–644.
- Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. *Lancet*. 1984;1:179–182.
- Robinson GM, Orrego H, Israel Y, et al. Low-molecular-weight polyethylene glycol as a probe of gastrointestinal permeability after alcohol ingestion. *Dig Dis Sci*. 1981;26:971–977.
- Mathurin P, Deng QG, Keshavarzian A, et al. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. *Hepatology*. 2000;32:1008–1017.
- Keshavarzian A, Farhadi A, Forsyth CB, et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. *J Hepatol*. 2009;50:538–547.
- Keshavarzian A, Choudhary S, Holmes EW, et al. Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats. *J Pharmacol Exp Ther*. 2001;299:442–448.
- Parlesak A, Schafer C, Schutz T, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. *J Hepatol*. 2000;32:742–747.
- Lambert JC, Zhou Z, Wang L, et al. Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. *J Pharmacol Exp Ther*. 2003;305:880–886.
- Adachi Y, Bradford BU, Gao W, et al. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. *Hepatology*. 1994;20:453–460.
- Nanji AA, Khettry U, Sadrzadeh SM. *Lactobacillus* feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). *Proc Soc Exp Biol Med*. 1994;205:243–247.
- McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. *Inflamm Bowel Dis*. 2009;15:100–113.
- Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. *Neurogastroenterol Motil*. 2007;19:545–552.
- Squier CA, Cox P, Hall BK. Enhanced penetration of nitrosonornicotine across oral mucosa in the presence of ethanol. *J Oral Pathol*. 1986;15:276–279.
- Howie NM, Trigkas TK, Cruchley AT, et al. Short-term exposure to alcohol increases the permeability of human oral mucosa. *Oral Dis*. 2001;7:349–354.
- Squier CA, Kremer MJ, Wertz PW. Effect of ethanol on lipid metabolism and epithelial permeability barrier of skin and oral mucosa in the rat. *J Oral Pathol Med*. 2003;32:595–599.
- Wight AJ, Ogden GR. Possible mechanisms by which alcohol may influence the development of oral cancer – a review. *Oral Oncol*. 1998;34:441–447.
- Halsted CH, Robles EA, Mezey E. Distribution of ethanol in the human gastrointestinal tract. *Am J Clin Nutr*. 1973;26:831–834.
- Zakhari S. Overview: how is alcohol metabolized by the body? *Alcohol Res Health*. 2006;29:245–254.
- Thomasson HR. Gender differences in alcohol metabolism. Physiological responses to ethanol. *Recent Dev Alcohol*. 1995;12:163–179.
- Mizoi Y, Yamamoto K, Ueno Y, et al. Involvement of genetic polymorphism of alcohol and aldehyde dehydrogenases in individual variation of alcohol metabolism. *Alcohol Alcohol*. 1994;29:707–710.
- Crabb DW, Bosron WF, Li TK. Ethanol metabolism. *Pharmacol Ther*. 1987;34:59–73.
- Levitt MD, Li R, DeMaster EG, et al. Use of measurements of ethanol absorption from stomach and intestine to assess human ethanol metabolism. *Am J Physiol*. 1997;273:G951–G957.
- Norberg A, Jones AW, Hahn RG, et al. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. *Clin Pharmacokinet*. 2003;42:1–31.
- Holford NH. Clinical pharmacokinetics of ethanol. *Clin Pharmacokinet*. 1987;13:273–292.
- Eckardt MJ, File SE, Gessa GL, et al. Effects of moderate alcohol consumption on the central nervous system. *Alcohol Clin Exp Res*. 1998;22:998–1040.
- Oneta CM, Simanowski UA, Martinez M, et al. First pass metabolism of ethanol is strikingly influenced by the speed of gastric emptying. *Gut*. 1998;43:612–619.
- Levitt MD, Doizaki W, Levine AS. Hypothesis: metabolic activity of the colonic bacteria influences organ injury from ethanol. *Hepatology*. 1982;2:598–600.



35. Jones AW. Distribution of ethanol between saliva and blood in man. *Clin Exp Pharmacol Physiol*. 1979;6:53–59.
36. Goist KC Jr, Sutker PB. Acute alcohol intoxication and body composition in women and men. *Pharmacol Biochem Behav*. 1985;22:811–814.
37. Lammers SM, Mainzer DE, Breteler MH. Do alcohol pharmacokinetics in women vary due to the menstrual cycle? *Addiction*. 1995;90:23–30.
38. Agarwal DP, Goedde HW. Pharmacogenetics of alcohol dehydrogenase (ADH). *Pharmacol Ther*. 1990;45:69–83.
39. Seitz HK, Oneta CM. Gastrointestinal alcohol dehydrogenase. *Nutr Rev*. 1998;56:52–60.
40. Seitz HK, Egerer G, Oneta C, et al. Alcohol dehydrogenase in the human colon and rectum. *Digestion*. 1996;57:105–108.
41. Vaglenova J, Martinez SE, Porte S, et al. Expression, localization and potential physiological significance of alcohol dehydrogenase in the gastrointestinal tract. *Eur J Biochem*. 2003;270:2652–2662.
42. Jorvall H, Danielsson O, Hjelmqvist L, et al. The alcohol dehydrogenase system. *Adv Exp Med Biol*. 1995;372:281–294.
43. Jorvall H, Hoog JO. Nomenclature of alcohol dehydrogenases. *Alcohol Alcohol*. 1995;30:153–161.
44. Jelski W, Szmikowski M. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. *Clin Chim Acta*. 2008;395:1–5.
45. Pestalozzi DM, Buhler R, von Wartburg JP, et al. Immunohistochemical localization of alcohol dehydrogenase in the human gastrointestinal tract. *Gastroenterology*. 1983;85:1011–1016.
46. Dong YJ, Peng TK, Yin SJ. Expression and activities of class IV alcohol dehydrogenase and class III aldehyde dehydrogenase in human mouth. *Alcohol*. 1996;13:257–262.
47. Yin SJ, Chou FJ, Chao SF, et al. Alcohol and aldehyde dehydrogenases in human esophagus: comparison with the stomach enzyme activities. *Alcohol Clin Exp Res*. 1993;17:376–381.
48. Pares X, Cederlund E, Moreno A, et al. Class IV alcohol dehydrogenase (the gastric enzyme). Structural analysis of human sigma sigma-ADH reveals class IV to be variable and confirms the presence of a fifth mammalian alcohol dehydrogenase class. *FEBS Lett*. 1992;303:69–72.
49. Westerlund M, Belin AC, Felder MR, et al. High and complementary expression patterns of alcohol and aldehyde dehydrogenases in the gastrointestinal tract: implications for Parkinson's disease. *FEBS J*. 2007;274:1212–1223.
50. Lieber CS, Gentry RT, Baraona E. First pass metabolism of ethanol. *Alcohol Alcohol Suppl*. 1994;2:163–169.
51. Caballeria J, Frezza M, Hernandez-Munoz R, et al. Gastric origin of the first-pass metabolism of ethanol in humans: effect of gastrectomy. *Gastroenterology*. 1989;97:1205–1209.
52. Julkunen RJ, Tannenbaum L, Baraona E, et al. First pass metabolism of ethanol: an important determinant of blood levels after alcohol consumption. *Alcohol*. 1985;2:437–441.
53. Lim RT, Jr, Gentry RT, Ito D, et al. First-pass metabolism of ethanol is predominantly gastric. *Alcohol Clin Exp Res*. 1993;17:1337–1344.
54. Lieber CS. Ethanol metabolism, cirrhosis and alcoholism. *Clin Chim Acta*. 1997;257:59–84.
55. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. *N Engl J Med*. 1990;322:95–99.
56. Seitz HK, Egerer G, Simanowski UA, et al. Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism. *Gut*. 1993;34:1433–1437.
57. Dohmen K, Baraona E, Ishibashi H, et al. Ethnic differences in gastric sigma-alcohol dehydrogenase activity and ethanol first-pass metabolism. *Alcohol Clin Exp Res*. 1996;20:1569–1576.
58. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. *Physiol Rev*. 1997;77:517–544.
59. Lieber CS, DeCarli LM. Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding. *Science*. 1968;162:917–918.
60. Ingelman-Sundberg M, Ronis MJ, Lindros KO, et al. Ethanol-inducible cytochrome P4502E1: regulation, enzymology and molecular biology. *Alcohol Alcohol Suppl*. 1994;2:131–139.
61. Beno I, Volkova K, Staruchova M, et al. The activity of Cu/Zn-superoxide dismutase and catalase of gastric mucosa in chronic gastritis, and the effect of alpha-tocopherol. *Bratisl Lek Listy*. 1994;95:9–14.
62. Lieber CS. Metabolism of alcohol. *Clin Liver Dis*. 2005;9:1–35.
63. Agarwal DP. Molecular genetic aspects of alcohol metabolism and alcoholism. *Pharmacopsychiatry*. 1997;30:79–84.
64. Bosron WF, Li TK. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. *Hepatology*. 1986;6:502–510.
65. Li TK, Bosron WF. Genetic variability of enzymes of alcohol metabolism in human beings. *Ann Emerg Med*. 1986;15:997–1004.
66. Salaspuro M. Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. *Ann Med*. 1996;28:195–200.
67. Li TK, Yin SJ, Crabb DW, et al. Genetic and environmental influences on alcohol metabolism in humans. *Alcohol Clin Exp Res*. 2001;25:136–144.
68. Freudenheim JL, Ambrosone CB, Moysich KB, et al. Alcohol dehydrogenase 3 genotype modification of the association of alcohol consumption with breast cancer risk. *Cancer Causes Control*. 1999;10:369–377.
69. Crabb DW, Edenberg HJ, Bosron WF, et al. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. *J Clin Invest*. 1989;83:314–316.
70. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. *Lancet Oncol*. 2007;8:292–293.
71. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat Rev Cancer*. 2007;7:599–612.
72. Moreira MT, Smith LA, Foxcroft D. Social norms interventions to reduce alcohol misuse in university or college students. *Cochrane Database Syst Rev*. 2009; (3):CD006748.
73. Best CA, Laposata M. Fatty acid ethyl esters: toxic non-oxidative metabolites of ethanol and markers of ethanol intake. *Front Biosci*. 2003;8:e202–e217.
74. Pannequin J, Delaunay N, Darido C, et al. Phosphatidylethanol accumulation promotes intestinal hyperplasia by inducing ZONAB-mediated cell density increase in response to chronic ethanol exposure. *Mol Cancer Res*. 2007; 5:1147–1157.
75. Aradottir S, Asanovska G, Gjerss S, et al. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. *Alcohol Alcohol*. 2006;41:431–437.
76. Varga A, Hansson P, Lundqvist C, et al. Phosphatidylethanol in blood as a marker of ethanol consumption in healthy volunteers: comparison with other markers. *Alcohol Clin Exp Res*. 1998;22:1832–1837.
77. Gnann H, Weinmann W, Thierauf A. Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. *Alcohol Clin Exp Res*. 2012;36:1507–1511.
78. Gunnarsson T, Karlsson A, Hansson P, et al. Determination of phosphatidylethanol in blood from alcoholic males using high-performance liquid chromatography and evaporative light scattering or electrospray mass spectrometric detection. *J Chromatogr B Biomed Sci Appl*. 1998;705:243–249.
79. Varga A, Hansson P, Johnson G, et al. Normalization rate and cellular localization of phosphatidylethanol in whole blood from chronic alcoholics. *Clin Chim Acta*. 2000;299:141–150.
80. Chen Q, Barros H, Floren CH, et al. Absorption and incorporation into tissue lipids of 3H-arachidonic- and 14C-linoleic acid: effects of ethanol in jejunal tissue cultures and in vivo. *Scand J Clin Lab Invest*. 1994;54:495–504.
81. Lange LG. Nonoxidative ethanol metabolism: formation of fatty acid ethyl esters by cholesterol esterase. *Proc Natl Acad Sci U S A*. 1982;79:3954–3957.
82. Laposata M. Fatty acid ethyl esters: nonoxidative ethanol metabolites with emerging biological and clinical significance. *Lipids*. 1999;34(Suppl):S281–S285.
83. Diczfalussy MA, Bjorkhem I, Einarsson C, et al. Characterization of enzymes involved in formation of ethyl esters of long-chain fatty acids in humans. *J Lipid Res*. 2001;42:1025–1032.
84. Kulaga V, Pragst F, Fulga N, et al. Hair analysis of fatty acid ethyl esters in the detection of excessive drinking in the context of fetal alcohol spectrum disorders. *Ther Drug Monit*. 2009;31:261–266.
85. Lange LG, Sobel BE. Mitochondrial dysfunction induced by fatty acid ethyl esters, myocardial metabolites of ethanol. *J Clin Invest*. 1983;72:724–731.
86. Wright M, Bieser KJ, Kinnunen PM, et al. Nonoxidative ethanol metabolism in human leukocytes: detection of fatty acid ethyl ester synthase activity. *Biochem Biophys Res Commun*. 1987;142:979–985.
87. Laposata EA, Scherrer DE, Mazow C, et al. Metabolism of ethanol by human brain to fatty acid ethyl esters. *J Biol Chem*. 1987;262:4653–4657.
88. Laposata EA, Scherrer DE, Lange LG. Fatty acid ethyl esters in adipose tissue. A laboratory marker for alcohol-related death. *Arch Pathol Lab Med*. 1989; 113:762–766.
89. Hutson JR, Aleksa K, Pragst F, et al. Detection and quantification of fatty acid ethyl esters in meconium by headspace-solid-phase microextraction and gas chromatography-mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci*. 2009;877:8–12.
90. Bakdash A, Burger P, Goecke TW, et al. Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. *Anal Bioanal Chem*. 2010;396:2469–2477.
91. Werner J, Saghir M, Fernandez-del Castillo C, et al. Linkage of oxidative and nonoxidative ethanol metabolism in the pancreas and toxicity of nonoxidative ethanol metabolites for pancreatic acinar cells. *Surgery*. 2001;129:736–744.
92. Refaai MA, Nguyen PN, Steffensen TS, et al. Liver and adipose tissue fatty acid ethyl esters obtained at autopsy are postmortem markers for pre-mortem ethanol intake. *Clin Chem*. 2002;48:77–83.
93. Borucki K, Kunstmann S, Dierkes J, et al. In heavy drinkers fatty acid ethyl esters in the serum are increased for 44 hr after ethanol consumption. *Alcohol Clin Exp Res*. 2004;28:1102–1106.
94. Borucki K, Dierkes J, Wartberg J, et al. In heavy drinkers, fatty acid ethyl esters remain elevated for up to 99 hours. *Alcohol Clin Exp Res*. 2007;31:423–427.

95. Wu H, Cai P, Clemens DL, et al. Metabolic basis of ethanol-induced cytotoxicity in recombinant HepG2 cells: role of nonoxidative metabolism. *Toxicol Appl Pharmacol.* 2006;216:238–247.
96. Blomstrand R. Observations of the formation of ethanol in the intestinal tract in man. *Life Sci* 11. 1971;10:575–582.
97. Krebs HA, Perkins JR. The physiological role of liver alcohol dehydrogenase. *Biochem J.* 1970;118:635–644.
98. Klipstein FA, Engert RF. Enterotoxigenic intestinal bacteria in tropical sprue. III. Preliminary characterization of *Klebsiella pneumoniae* enterotoxin. *J Infect Dis.* 1975;132:200–203.
99. Mezey E, Imbembo AL, Potter JJ, et al. Endogenous ethanol production and hepatic disease following jejunoileal bypass for morbid obesity. *Am J Clin Nutr.* 1975;28:1277–1283.
100. Lin Y, Tanaka S. Ethanol fermentation from biomass resources: current state and prospects. *Appl Microbiol Biotechnol.* 2006;69:627–642.
101. Roine RP, Salmela KS, Salaspuro M. Alcohol metabolism in *Helicobacter pylori*-infected stomach. *Ann Med.* 1995;27:583–588.
102. Still JL. Alcohol enzyme of *Bact. coli*. *Biochem J.* 1940;34:1177–1182.
103. Baraona E, Julkunen R, Tannenbaum L, et al. Role of intestinal bacterial overgrowth in ethanol production and metabolism in rats. *Gastroenterology.* 1986;90:103–110.
104. Kurkivuori J, Salaspuro V, Kaihovaara P, et al. Acetaldehyde production from ethanol by oral streptococci. *Oral Oncol.* 2007;43:181–186.
105. Tillonen J, Homann N, Rautio M, et al. Role of yeasts in the salivary acetaldehyde production from ethanol among risk groups for ethanol-associated oral cavity cancer. *Alcohol Clin Exp Res.* 1999;23:1409–1415.
106. Roine RP, Salmela KS, Hook-Nikanne J, et al. Alcohol dehydrogenase mediated acetaldehyde production by *Helicobacter pylori* – a possible mechanism behind gastric injury. *Life Sci.* 1992;51:1333–1337.
107. Jokelainen K, Siitonen A, Jousimies-Somer H, et al. In vitro alcohol dehydrogenase-mediated acetaldehyde production by aerobic bacteria representing the normal colonic flora in man. *Alcohol Clin Exp Res.* 1996;20:967–972.
108. Salaspuro V, Nyfors S, Heine R, et al. Ethanol oxidation and acetaldehyde production in vitro by human intestinal strains of *Escherichia coli* under aerobic, microaerobic, and anaerobic conditions. *Scand J Gastroenterol.* 1999;34:967–973.
109. Macconi E, Griffini A, Cavazzoni V, et al. Reduction of acetaldehyde to ethanol by some micro-organisms and its stereospecificity. *Biochem J.* 1988;250:929–932.
110. Tillonen J, Kaihovaara P, Jousimies-Somer H, et al. Role of catalase in in vitro acetaldehyde formation by human colonic contents. *Alcohol Clin Exp Res.* 1998;22:1113–1119.
111. Jokelainen K, Roine RP, Vaananen H, et al. In vitro acetaldehyde formation by human colonic bacteria. *Gut.* 1994;35:1271–1274.
112. Seitz HK, Simanowski UA, Garzon FT, et al. Possible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. *Gastroenterology.* 1990;98:406–413.
113. Tillonen J, Vakevainen S, Salaspuro V, et al. Metronidazole increases intracolonic but not peripheral blood acetaldehyde in chronic ethanol-treated rats. *Alcohol Clin Exp Res.* 2000;24:570–575.
114. Jokelainen K, Matysiak-Budnik T, Makisalo H, et al. High intracolonic acetaldehyde values produced by a bacteriocolonic pathway for ethanol oxidation in piglets. *Gut.* 1996;39:100–104.
115. Visapaa JP, Jokelainen K, Nosova T, et al. Inhibition of intracolonic acetaldehyde production and alcoholic fermentation in rats by ciprofloxacin. *Alcohol Clin Exp Res.* 1998;22:1161–1164.
116. Nosova T, Jokelainen K, Kaihovaara P, et al. Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. *Alcohol Alcohol.* 1996;31:555–564.
117. Nosova T, Jokelainen K, Kaihovaara P, et al. Characteristics of aldehyde dehydrogenases of certain aerobic bacteria representing human colonic flora. *Alcohol Alcohol.* 1998;33:273–280.
118. Koivisto T, Salaspuro M. Aldehyde dehydrogenases of the rat colon: comparison with other tissues of the alimentary tract and the liver. *Alcohol Clin Exp Res.* 1996;20:551–555.
119. Seitz HK, Homann N. The role of acetaldehyde in alcohol-associated cancer of the gastrointestinal tract. *Novartis Found Symp.* 2007;285:110–119; discussion 119–124, 198–199.
120. Yan AW, Fouts DE, Brandt J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. *Hepatology.* 2011;53:96–105.
121. Mutlu E, Keshavarzian A, Engen P, et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. *Alcohol Clin Exp Res.* 2009;33:1836–1846.
122. Bode JC, Bode C, Heidelbach R, et al. Jejunal microflora in patients with chronic alcohol abuse. *Hepatogastroenterology.* 1984;31:30–34.
123. Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. *Dig Dis Sci.* 1996;41:552–556.
124. Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. *Am J Physiol Gastrointest Liver Physiol.* 2012;302:G966–G978.
125. Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, et al. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. *Am J Clin Nutr.* 2012;95:1323–1334.
126. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology.* 2011;54:562–572.
127. Forsyth CB, Farhadi A, Jakate SM, et al. *Lactobacillus* GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. *Alcohol.* 2009;43:163–172.
128. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. *Hepatology.* 2004;39:1441–1449.
129. Nosova T, Jousimies-Somer H, Jokelainen K, et al. Acetaldehyde production and metabolism by human indigenous and probiotic *Lactobacillus* and *Bifidobacterium* strains. *Alcohol Alcohol.* 2000;35:561–568.
130. Baumgart DC, Dignass AU. Intestinal barrier function. *Curr Opin Clin Nutr Metab Care.* 2002;5:685–694.
131. Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol.* 2009;9:799–809.
132. Van Itallie CM, Anderson JM. The molecular physiology of tight junction pores. *Physiology (Bethesda).* 2004;19:331–338.
133. Blair SA, Kane SV, Clayburgh DR, et al. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. *Lab Invest.* 2006;86:191–201.
134. Gopalakrishnan S, Raman N, Atkinson SJ, et al. Rho GTPase signaling regulates tight junction assembly and protects tight junctions during ATP depletion. *Am J Physiol.* 1998;275:C798–C809.
135. Jain S, Suzuki T, Seth A, et al. Protein kinase C $\zeta$  phosphorylates occludin and promotes assembly of epithelial tight junctions. *Biochem J.* 2011;437:289–299.
136. Samak G, Aggarwal S, Rao RK. ERK is involved in EGF-mediated protection of tight junctions, but not adherens junctions, in acetaldehyde-treated Caco-2 cell monolayers. *Am J Physiol Gastrointest Liver Physiol.* 2011;301:G50–G59.
137. Atkinson KJ, Rao RK. Role of protein tyrosine phosphorylation in acetaldehyde-induced disruption of epithelial tight junctions. *Am J Physiol Gastrointest Liver Physiol.* 2001;280:G1280–G1288.
138. Samak G, Narayanan D, Jaggar JH, et al. CaV1.3 channels and intracellular calcium mediate osmotic stress-induced N-terminal c-Jun kinase activation and disruption of tight junctions in Caco-2 cell monolayers. *J Biol Chem.* 2011;286:30232–30243.
139. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. *Physiol Rev.* 2011;91:151–175.
140. Gonzalez-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. *Biochim Biophys Acta.* 2008;1778:729–756.
141. Lichtenberger LM, Zhou Y, Dial EJ, et al. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. *J Pharm Pharmacol.* 2006;58:1421–1428.
142. Watson CJ, Hoare CJ, Garrod DR, et al. Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. *J Cell Sci.* 2005;118:5221–5230.
143. Wang F, Graham WV, Wang Y, et al. Interferon-gamma and tumor necrosis factor- $\alpha$  synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. *Am J Pathol.* 2005;166:409–419.
144. Al-Sadi R, Ye D, Said HM, et al. Cellular and molecular mechanism of interleukin-1 $\beta$  modulation of Caco-2 intestinal epithelial tight junction barrier. *J Cell Mol Med.* 2011;15:970–982.
145. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. *Am J Physiol Gastrointest Liver Physiol.* 2000;279:G851–G857.
146. Menzies IS. Intestinal permeability in coeliac disease. *Gut.* 1972;13:847.
147. Menzies IS, Laker MF, Pounder R, et al. Abnormal intestinal permeability to sugars in villous atrophy. *Lancet.* 1979;2:1107–1109.
148. Grootjans J, Thuijls G, Verdam F, et al. Non-invasive assessment of barrier integrity and function of the human gut. *World J Gastrointest Surg.* 2010;2:61–69.
149. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. *Gastroenterology.* 1995;108:1566–1581.
150. Hirsch S, Chaves G, Gotteland M, et al. Intestinal permeability in alcoholic patients without liver damage [in Spanish]. *Rev Med Chil.* 1997;125:653–658.
151. Keshavarzian A, Fields JZ, Vaeth J, et al. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. *Am J Gastroenterol.* 1994;89:2205–2211.
152. Farhadi A, Keshavarzian A, Kwasny MJ, et al. Effects of aspirin on gastroduodenal permeability in alcoholics and controls. *Alcohol.* 2010;44:447–456.

153. Lee S, Son SC, Han MJ, et al. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. *World J Gastroenterol*. 2008;14:3884–3890.
154. Swanson GR, Tieu V, Shaikh M, et al. Is moderate red wine consumption safe in inactive inflammatory bowel disease? *Digestion*. 2011;84:238–244.
155. Millan MS, Morris GP, Beck IT, et al. Villous damage induced by suction biopsy and by acute ethanol intake in normal human small intestine. *Dig Dis Sci*. 1980;25:513–525.
156. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. *J Hepatol*. 1987;4:8–14.
157. Keshavarzian A, Holmes EW, Patel M, et al. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. *Am J Gastroenterol*. 1999;94:200–207.
158. Bode C, Vollmer E, Hug J, et al. Increased permeability of the gut to polyethylene glycol and dextran in rats fed alcohol. *Ann NY Acad Sci*. 1991;625:837–840.
159. Dinda PK, Kossev P, Beck IT, et al. Role of xanthine oxidase-derived oxidants and leukocytes in ethanol-induced jejunal mucosal injury. *Dig Dis Sci*. 1996;41:2461–2470.
160. Simanowski UA, Seitz HK, Baier B, et al. Chronic ethanol consumption selectively stimulates rectal cell proliferation in the rat. *Gut*. 1986;27:278–282.
161. McGarrity TJ, Peiffer LP, Colony PC, et al. The effects of chronic ethanol administration on polyamine content during dimethylhydrazine-induced colorectal carcinogenesis in the rat. *Carcinogenesis*. 1988;9:2093–2098.
162. Kavanaugh MJ, Clark C, Goto M, et al. Effect of acute alcohol ingestion prior to burn injury on intestinal bacterial growth and barrier function. *Burns*. 2005;31:290–296.
163. Choudhry MA, Fazal N, Goto M, et al. Gut-associated lymphoid T cell suppression enhances bacterial translocation in alcohol and burn injury. *Am J Physiol Gastrointest Liver Physiol*. 2002;282:G937–G947.
164. Ferrier L, Berard F, Debrauwer L, et al. Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. *Am J Pathol*. 2006;168:1148–1154.
165. Rao RK. Acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. *Alcohol Clin Exp Res*. 1998;22:1724–1730.
166. Ma TY, Nguyen D, Bui V, et al. Ethanol modulation of intestinal epithelial tight junction barrier. *Am J Physiol*. 1999;276:G965–G974.
167. Banan A, Choudhary S, Zhang Y, et al. Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. *J Pharmacol Exp Ther*. 1999;291:1075–1085.
168. Banan A, Smith GS, Kokoska ER, et al. Role of actin cytoskeleton in prostaglandin-induced protection against ethanol in an intestinal epithelial cell line. *J Surg Res*. 2000;88:104–113.
169. Rao RK, Seth A, Sheth P. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. *Am J Physiol Gastrointest Liver Physiol*. 2004;286:G881–G884.
170. Bode JC, Knuppel H, Schwerk W, et al. Quantitative histomorphometric study of the jejunal mucosa in chronic alcoholics. *Digestion*. 1982;23:265–270.
171. Gottfried EB, Korsten MA, Lieber CS. Alcohol-induced gastric and duodenal lesions in man. *Am J Gastroenterol*. 1978;70:587–592.
172. Brozinsky S, Fani K, Grosberg SJ, et al. Alcohol ingestion-induced changes in the human rectal mucosa: light and electron microscopic studies. *Dis Colon Rectum*. 1978;21:329–335.
173. Tamai H, Kato S, Horie Y, et al. Effect of acute ethanol administration on the intestinal absorption of endotoxin in rats. *Alcohol Clin Exp Res*. 2000;24:390–394.
174. Napolitano LM, Koruda MJ, Zimmerman K, et al. Chronic ethanol intake and burn injury: evidence for synergistic alteration in gut and immune integrity. *J Trauma*. 1995;38:198–207.
175. Rossi MA, Zucoloto S. Effect of chronic ethanol ingestion on the small intestinal ultrastructure in rats. *Beitr Pathol*. 1977;161:50–61.
176. Asai K, Buurman WA, Reutelingsperger CP, et al. Modular effects of estradiol on ethanol-induced apoptosis in human intestinal epithelial cells. *Scand J Gastroenterol*. 2005;40:326–335.
177. Laurent C, Besancon P, Caporiccio B. Ethanol and polyphenolic free wine matrix stimulate the differentiation of human intestinal Caco-2 cells. Influence of their association with a procyanidin-rich grape seed extract. *J Agric Food Chem*. 2005;53:5541–5548.
178. Amin PB, Diebel LN, Liberati DM. Dose-dependent effects of ethanol and *E. coli* on gut permeability and cytokine production. *J Surg Res*. 2009;157:187–192.
179. Koivisto T, Salaspuro M. Acetaldehyde alters proliferation, differentiation and adhesion properties of human colon adenocarcinoma cell line Caco-2. *Carcinogenesis*. 1998;19:2031–2036.
180. Criddle DN, Raraty MG, Neoptolemos JP, et al. Ethanol toxicity in pancreatic acinar cells: mediation by nonoxidative fatty acid metabolites. *Proc Natl Acad Sci U S A*. 2004;101:10738–10743.
181. Elamin E, Masclee A, Juuti-Uusitalo K, et al. Fatty acid ethyl esters induce intestinal epithelial barrier dysfunction via a reactive oxygen species-dependent mechanism in a three-dimensional cell culture model. *PLoS One*. 2013;8:e58561.
182. Rao RK. Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. *Methods Mol Biol*. 2008;447:171–183.
183. Seth A, Basuroy S, Sheth P, et al. L-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. *Am J Physiol Gastrointest Liver Physiol*. 2004;287:G510–G517.
184. Sheth P, Seth A, Thangavel M, et al. Epidermal growth factor prevents acetaldehyde-induced paracellular permeability in Caco-2 cell monolayer. *Alcohol Clin Exp Res*. 2004;28:797–804.
185. Sheth P, Seth A, Atkinson KJ, et al. Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. *Biochem J*. 2007;402:291–300.
186. Basuroy S, Sheth P, Mansbach CM, et al. Acetaldehyde disrupts tight junctions and adherens junctions in human colonic mucosa: protection by EGF and L-glutamine. *Am J Physiol Gastrointest Liver Physiol*. 2005;289:G367–G375.
187. Banan A, Keshavarzian A, Zhang L, et al. NF-kappaB activation as a key mechanism in ethanol-induced disruption of the F-actin cytoskeleton and monolayer barrier integrity in intestinal epithelium. *Alcohol*. 2007;41:447–460.
188. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136:215–233.
189. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. *Mol Cell Pharmacol*. 2011;3:83–92.
190. Swanson G, Forsyth CB, Tang Y, et al. Role of intestinal circadian genes in alcohol-induced gut leakiness. *Alcohol Clin Exp Res*. 2011;35:1305–1314.
191. Zhong W, Zhao Y, McClain CJ, et al. Inactivation of hepatocyte nuclear factor-4 $\alpha$  mediates alcohol-induced downregulation of intestinal tight junction proteins. *Am J Physiol Gastrointest Liver Physiol*. 2010;299:G643–G651.
192. Tang Y, Banan A, Forsyth CB, et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. *Alcohol Clin Exp Res*. 2008;32:355–364.
193. Forsyth CB, Tang Y, Shaikh M, et al. Role of snail activation in alcohol-induced iNOS-mediated disruption of intestinal epithelial cell permeability. *Alcohol Clin Exp Res*. 2011;35:1635–1643.
194. Elamin E, Jonkers D, Juuti-Uusitalo K, et al. Effects of ethanol and acetaldehyde on tight junction integrity: in vitro study in a three dimensional intestinal epithelial cell culture model. *PLOS ONE*. 2012;7:e35008.
195. Varella Morandi Junqueira-Franco M, Ernesto Troncon L, Garcia Chiarello P, et al. Intestinal permeability and oxidative stress in patients with alcoholic pellagra. *Clin Nutr*. 2006;25:977–983.
196. Banan A, Fields JZ, Decker H, et al. Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. *J Pharmacol Exp Ther*. 2000;294:997–1008.
197. Tang Y, Forsyth CB, Farhadi A, et al. Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. *Alcohol Clin Exp Res*. 2009;33:1220–1230.
198. Zhong W, McClain CJ, Cave M, et al. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. *Am J Physiol Gastrointest Liver Physiol*. 2010;298:G625–G633.
199. Suzuki T, Seth A, Rao R. Role of phospholipase Cgamma-induced activation of protein kinase Cepsilon (PKCepsilon) and PKCbeta1 in epidermal growth factor-mediated protection of tight junctions from acetaldehyde in Caco-2 cell monolayers. *J Biol Chem*. 2008;283:3574–3583.
200. Basuroy S, Sheth P, Kuppuswamy D, et al. Expression of kinase-inactive c-Src delays oxidative stress-induced disassembly and accelerates calcium-mediated reassembly of tight junctions in the Caco-2 cell monolayer. *J Biol Chem*. 2003;278:11916–11924.
201. Rao RK, Basuroy S, Rao VU, et al. Tyrosine phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress. *Biochem J*. 2002;368:471–481.
202. Rao RK, Li L, Baker RD, et al. Glutathione oxidation and PTPase inhibition by hydrogen peroxide in Caco-2 cell monolayer. *Am J Physiol Gastrointest Liver Physiol*. 2000;279:G332–G340.
203. Seth A, Sheth P, Elias BC, et al. Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer. *J Biol Chem*. 2007;282:11487–11498.
204. Sheth P, Basuroy S, Li C, et al. Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions. *J Biol Chem*. 2003;278:49239–49245.
205. Petersen OH, Tepikin AV, Gerasimenko JV, et al. Fatty acids, alcohol and fatty acid ethyl esters: toxic Ca<sup>2+</sup> signal generation and pancreatitis. *Cell Calcium*. 2009;45:634–642.
206. Wu H, Bhopale KK, Ansari GA, et al. Ethanol-induced cytotoxicity in rat pancreatic acinar AR42J cells: role of fatty acid ethyl esters. *Alcohol Alcohol*. 2008;43:1–8.
207. Aydin HH, Celik HA, Deveci R, et al. Induction of apoptosis by fatty acid ethyl esters in HepG2 cells. *Food Chem Toxicol*. 2005;43:139–145.

208. Hietbrink F, Besselink MG, Renooij W, et al. Systemic inflammation increases intestinal permeability during experimental human endotoxemia. *Shock*. 2009;32:374–378.
209. Rivera CA, Bradford BU, Seabra V, et al. Role of endotoxin in the hypermetabolic state after acute ethanol exposure. *Am J Physiol Gastrointest Liver Physiol*. 1998;275:G1252–G1258.
210. Zhou Z, Wang L, Song Z, et al. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF- $\alpha$  production. *Am J Pathol*. 2003;163:1137–1146.
211. Guntaka SR, Samak G, Seth A, et al. Epidermal growth factor protects the apical junctional complexes from hydrogen peroxide in bile duct epithelium. *Lab Invest*. 2011;91:1396–1409.
212. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? *Trends Cell Biol*. 1999;9:268–273.
213. Fukui H, Brauner B, Bode JC, et al. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. *J Hepatol*. 1991;12:162–169.
214. Forsythe RM, Xu DZ, Lu Q, et al. Lipopolysaccharide-induced enterocyte-derived nitric oxide induces intestinal monolayer permeability in an autocrine fashion. *Shock*. 2002;17:180–184.
215. Gu L, Li N, Gong J, et al. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxemia. *J Infect Dis*. 2011;203:1602–1612.
216. Simonovic I, Arpin M, Koutsouris A, et al. Enteropathogenic *Escherichia coli* activates ezrin, which participates in disruption of tight junction barrier function. *Infect Immun*. 2001;69:5679–5688.
217. Shifflett DE, Clayburgh DR, Koutsouris A, et al. Enteropathogenic *E. coli* disrupts tight junction barrier function and structure in vivo. *Lab Invest*. 2005;85:1308–1324.
218. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the probiotic effects of *Escherichia coli* Nissle 1917 involve ZO-2 and PKC $\zeta$  redistribution resulting in tight junction and epithelial barrier repair. *Cell Microbiol*. 2007;9:804–816.
219. Ukena SN, Singh A, Dringenberg U, et al. Probiotic *Escherichia coli* Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. *PLoS ONE*. 2007;2:e1308.
220. Ewaschuk JB, Diaz H, Meddings L, et al. Secreted bioactive factors from *Bifidobacterium infantis* enhance epithelial cell barrier function. *Am J Physiol Gastrointest Liver Physiol*. 2008;295:G1025–G1034.
221. Anderson RC, Cookson AL, McNabb WC, et al. *Lactobacillus plantarum* MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. *BMC Microbiol*. 2010;10:316.
222. Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by *Lactobacillus plantarum* in vivo and protective effects on the epithelial barrier. *Am J Physiol Gastrointest Liver Physiol*. 2010;298:G851–G859.
223. Adachi Y, Moore LE, Bradford BU, et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. *Gastroenterology*. 1995;108:218–224.
224. Tang Y, Forsyth CB, Banan A, et al. Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. *J Pharmacol Exp Ther*. 2009;329:952–958.
225. Wang Y, Kirpich I, Liu Y, et al. *Lactobacillus rhamnosus* GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. *Am J Pathol*. 2011;179:2866–2875.
226. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. *Alcohol*. 2008;42:675–682.